BRPI0822002A2 - tratamento de doenças de cólon ou prevenção de carcinoma colorretal com derivados de imidazoquinolina. - Google Patents

tratamento de doenças de cólon ou prevenção de carcinoma colorretal com derivados de imidazoquinolina.

Info

Publication number
BRPI0822002A2
BRPI0822002A2 BRPI0822002A BRPI0822002A BRPI0822002A2 BR PI0822002 A2 BRPI0822002 A2 BR PI0822002A2 BR PI0822002 A BRPI0822002 A BR PI0822002A BR PI0822002 A BRPI0822002 A BR PI0822002A BR PI0822002 A2 BRPI0822002 A2 BR PI0822002A2
Authority
BR
Brazil
Prior art keywords
prevention
treatment
colorectal carcinoma
colon disease
imidazoquinoline derivatives
Prior art date
Application number
BRPI0822002A
Other languages
English (en)
Portuguese (pt)
Inventor
Istvan Szelenyi
Joachim Maus
Ursula Petzold
Original Assignee
Meda Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40419193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0822002(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Meda Ab filed Critical Meda Ab
Publication of BRPI0822002A2 publication Critical patent/BRPI0822002A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
BRPI0822002A 2008-01-15 2008-12-23 tratamento de doenças de cólon ou prevenção de carcinoma colorretal com derivados de imidazoquinolina. BRPI0822002A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US645908P 2008-01-15 2008-01-15
PCT/EP2008/011088 WO2009089900A1 (en) 2008-01-15 2008-12-23 Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives

Publications (1)

Publication Number Publication Date
BRPI0822002A2 true BRPI0822002A2 (pt) 2015-10-13

Family

ID=40419193

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0822002A BRPI0822002A2 (pt) 2008-01-15 2008-12-23 tratamento de doenças de cólon ou prevenção de carcinoma colorretal com derivados de imidazoquinolina.

Country Status (15)

Country Link
US (1) US8008319B2 (https=)
EP (1) EP2237780A1 (https=)
JP (1) JP2011509956A (https=)
CN (1) CN101909624A (https=)
AU (1) AU2008347400B2 (https=)
BR (1) BRPI0822002A2 (https=)
CA (1) CA2708559C (https=)
EA (1) EA018579B1 (https=)
GE (1) GEP20125605B (https=)
IL (1) IL205819A (https=)
MX (1) MX2010007699A (https=)
NZ (1) NZ586161A (https=)
UA (1) UA101339C2 (https=)
WO (1) WO2009089900A1 (https=)
ZA (1) ZA201003906B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962652B2 (en) 2009-10-22 2015-02-24 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
CN105899539B (zh) 2014-01-10 2021-11-09 博笛生物科技有限公司 用于免疫疗法的化合物和组合物
EP3166976B2 (en) 2014-07-09 2026-04-08 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
IL312120B2 (en) * 2017-06-23 2025-06-01 Birdie Biopharmaceuticals Inc Pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2078547C1 (ru) * 1995-11-28 1997-05-10 Центральный научно-исследовательский рентгено-радиологический институт МЗМП РФ Способ лечения полипоза желудка и двенадцатиперстной кишки
UA75622C2 (en) * 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
EP1351678A2 (en) * 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
US20060193789A1 (en) * 2002-10-25 2006-08-31 Foamix Ltd. Film forming foamable composition
DE602004014969D1 (de) * 2003-11-21 2008-08-21 Novartis Ag 1h-imidazochinolinderivate als proteinkinaseinhibitoren

Also Published As

Publication number Publication date
EP2237780A1 (en) 2010-10-13
JP2011509956A (ja) 2011-03-31
AU2008347400A1 (en) 2009-07-23
MX2010007699A (es) 2010-08-04
ZA201003906B (en) 2011-03-30
CA2708559C (en) 2015-10-06
EA018579B1 (ru) 2013-09-30
UA101339C2 (ru) 2013-03-25
US20090182005A1 (en) 2009-07-16
IL205819A (en) 2013-02-28
AU2008347400B2 (en) 2014-12-11
WO2009089900A1 (en) 2009-07-23
EA201001164A1 (ru) 2010-12-30
US8008319B2 (en) 2011-08-30
CA2708559A1 (en) 2009-07-23
CN101909624A (zh) 2010-12-08
NZ586161A (en) 2012-05-25
GEP20125605B (en) 2012-08-10
IL205819A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
BRPI0822002A2 (pt) tratamento de doenças de cólon ou prevenção de carcinoma colorretal com derivados de imidazoquinolina.
BRPI0814889A2 (pt) tratamento com ligantes alfa7-seletivos.
BR112012002124A2 (pt) tratamento da doença de crohn com laquinimode.
BRPI0912683A2 (pt) tratamento de tumores metastáticos
IL242169A0 (en) Activin-actriia antagonists and uses for treating or preventing breast cancer
BRPI0920104A2 (pt) tratamento de soluções ou de águas residuais
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
FR2921499B1 (fr) Structure orientable de type catheter ou endoscope
BRPI0906436A2 (pt) Derivados de ftalazinona
FR2932478B1 (fr) Composes utiles pour le traitement des cancers.
HUE043326T2 (hu) Akut limfoblasztos leukémia kezelése
BRPI0917321A2 (pt) prevenção, tratamento e diagnóstico de infecção por p. gingivalis
NO345064B1 (no) Anvendelse av kombinasjonslegemidler, omfattende antimykotika
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
BRPI1016117A8 (pt) derivados de isoxazol-isoxazol e isoxazol-isotiazol.
BRPI1008517A2 (pt) direcionamento duplo de mir-208 e mir-499 no tratamento de doenças cardíacas.
BRPI0813364A2 (pt) Métodos de diagnóstico e tratamento de câncer.
SI2229369T1 (sl) Derivati 6,7-dialkoksi kinazolina, uporabni za zdravljenje motenj, povezanih z rakom
BRPI0718850A2 (pt) Métodos de tratar, diagnosticar ou detectar câncer
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
PL2430452T3 (pl) Diagnoza i leczenie raka w oparciu o genotyp odc1
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
DK2147122T3 (da) Enzymatisk kræftbehandling
BRPI0719920A2 (pt) Derivados de quinolina antibacterianos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]